Skip to content

Aboleris Holdco

Active
Public limited companyfounded 20233 yrs activeRue Antoine de Saint-Exupéry 14, 6041 Charleroi, BelgiumKBO/BCE: BE 0803.217.012
Summary

Aboleris Holdco has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €14.3m and a net result of -€5.8m. Equity is growing by ~7.2% per year across the filed fiscal years. Its solvency ranks better than 90% of 239 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisWatch ReportCompare
Aboleris HoldcoActiveChecked score 96/100
Risk analysis ReportCompare

Overview

Activity
Research and development on biotechnology
NACE 72101NACE 72110
#2 company by equity in Charleroi, Professional and technical services sector1 site
Size
€14.8mtotal assets 2025
Equity
€14.3m
Loss
-€5.8m
Financial health
96 Excellent Checked score 2025
Bankruptcy chance 12 m
0.1%
Structure
Largest shareholder
Newton Biocapital I, pricaf privée de droit belge · 25.69%
Holdings
1
Auditor: BDO Réviseurs d'Entreprises SRLAccounts 42 d early1 of 9 deeds read
Why 96- Loss of €5.8m, the second in a row (FY 2025)+ Size: total assets €14.8m+ Sector Scientific research and development (NACE 72)+ Figures for FY 2025 (filed 19-06-2026)Show the evidence

Checked score

Score 2025
96 / 100
Excellent
Probability in this band: under 0.55%
Better than 64% of its sector peers (NACE 72, medium-sized)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Average
Solvency 100=
equity 96.6% of total assets
Liquidity 58-23
short-term debt 3.4% · cash 6.0%
Profitability 0=
return on assets -39.2%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (47 companies)
Last 24 months 11-2024: 0.1% 12-2024: 0.1%▲ +0.8% vs 11-2024 01-2025: 0.1%● 0.0% vs 12-2024 02-2025: 0.1%▲ +2.4% vs 01-2025 03-2025: 0.1%▲ +3.9% vs 02-2025 04-2025: 0.1%▲ +12.8% vs 03-2025highest value 05-2025: 0.1%▼ -6.7% vs 04-2025 06-2025: 0.1%▼ -11.4% vs 05-2025 07-2025: 0.1%● 0.0% vs 06-2025 08-2025: 0.1%● 0.0% vs 07-2025 09-2025: 0.1%● 0.0% vs 08-2025 10-2025: 0.1%● 0.0% vs 09-2025 11-2025: 0.1%● 0.0% vs 10-2025 12-2025: 0.1%● 0.0% vs 11-2025 01-2026: 0.1%● 0.0% vs 12-2025 02-2026: 0.1%▼ -0.8% vs 01-2026 03-2026: 0.1%● 0.0% vs 02-2026 04-2026: 0.1%▲ +13.0% vs 03-2026 05-2026: 0.1%▼ -58.3% vs 04-2026lowest value 06-2026: 0.1%▲ +15.5% vs 05-2026 07-2026: 0.1%▲ +28.4% vs 06-2026 08-2026: 0.1%● 0.0% vs 07-2026 09-2026: 0.1%● 0.0% vs 08-2026 10-2026: 0.1%▲ +1.2% vs 09-2026
  • Size: total assets €14.8m lowers the probability for this profile
  • Sector Scientific research and development (NACE 72) lowers the probability
  • Loss of €5.8m, the second in a row (FY 2025) raises the probability
  • Figures for FY 2025 (filed 19-06-2026) lowers the probability
Credit up to €1,350,000 at 30 days acceptable
Liquidity ample (current ratio 9.95 against 5.25 in 2024; short-term debt: 3.4% and cash: 6% of total assets), and 3.4% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 72, medium-sized). Better than this share of them on solvency 90%, liquidity 72%, profitability 11%, growth against the median 83%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 05-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Size: total assets €14.8m
In the bankruptcy model this factor lowers the probability for this profile.
NBB · annual accounts
lowers risk · Sector Scientific research and development (NACE 72)
In the bankruptcy model this factor lowers the probability.
KBO
raises risk · Loss of €5.8m, the second in a row (FY 2025)
In the bankruptcy model this factor raises the probability.
NBB · annual accounts
lowers risk · Figures for FY 2025 (filed 19-06-2026)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-06-2026, 42 days ahead of the deadline.
NBB · 3 filings
Deviation from the deadline
2025
42 d early
2024
86 d early
2023
125 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 3 accounts on average 84 days before the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 6 May (3 of the last 3 filed years within 44 days of that day).
Companies Code · seven months
Position in the running window
06-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Reappointment: BDO Réviseurs d'Entreprises SRL (statutory…State Gazette act
  2. Annual accounts filedfiscal year 2025 · full…
  3. Annual accounts filedfiscal year 2024 · full…

Key points

  • Risk: 3 loss-making years in a rowloss fiscal year 2025 -€5.8m View
  • Caution: Among the weakest 8% on net resultsector median €4,111 · 236 companies -€5.8m View
  • Positive: Result rose in 2025from -€7.8m to -€5.8m ▲ 25.4% View

By topic

Financials

Fiscal year
2025
Total assets
€14.8m
Loss
-€5.8m
Solvency
96.6%
Total assets▲ 11.6%
Net result
20232025
Go to Financials

Board & ownership

Largest shareholder
Newton Biocapital I, pricaf… · 25.69%
Auditor
BDO Réviseurs d'Entreprises SRL
Go to Board & ownership

Timeline

Events
5
Since
2024
Next accounts
by 31-07-2027
  1. 28-09-2026Reappointment: BDO Réviseurs d'Entreprises SRL (statutory auditor)
  2. 19-06-2026Annual accounts filed
  3. 06-05-2025Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Research and development on biotechnologyNACE 72101
Founded
27-06-2023
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure